Update shared on04 Sep 2025
With no change in revenue growth forecasts or discount rate, MetLife’s fair value estimate remains steady at $91.86.
What's in the News
- MetLife will redeem all outstanding shares of its 3.850% Fixed Rate Reset Non-Cumulative Preferred Stock, Series G, at $1,000 per share; dividends of $19.250 per share will be paid separately, and all further dividends cease post-redemption.
- From April 1 to June 30, 2025, MetLife repurchased 6,546,520 shares (0.97%) for $510.08 million, completing a total of 38,597,576 shares (5.59%) for $3,071.19 million under the buyback announced May 1, 2024.
- From April 30 to July 31, 2025, the company repurchased 2,686,822 shares (0.4%) for $211.1 million under a separate buyback announced April 30, 2025.
- MetLife has been added to the Russell 1000 Defensive Index and Russell 1000 Value-Defensive Index.
- MetLife entered a strategic partnership with Sprout.ai to expand AI-driven claims automation across the US, Asia, and LATAM, following successful results in Latin America.
Valuation Changes
Summary of Valuation Changes for MetLife
- The Consensus Analyst Price Target remained effectively unchanged, at $91.86.
- The Consensus Revenue Growth forecasts for MetLife remained effectively unchanged, at 4.7% per annum.
- The Discount Rate for MetLife remained effectively unchanged, at 7.68%.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.